As of 2024-07-27, the Relative Valuation of BioMark Diagnostics Inc (BUX.CN) is (0.01) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.25 CAD, the upside of BioMark Diagnostics Inc based on Relative Valuation is -102.4%.
The range of the Relative Valuation is (0.01) - (0.10) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.3x - 6.5x | 0.4x |
| Forward P/E multiples | 0.2x - 6.0x | 0.3x |
| Fair Price | (0.01) - (0.10) | (0.01) |
| Upside | -102.2% - -141.4% | -102.4% |
| Date | P/E |
| 2024-07-26 | -13.89 |
| 2024-07-25 | -14.48 |
| 2024-07-19 | -13.00 |
| 2024-07-16 | -13.00 |
| 2024-07-12 | -13.00 |
| 2024-07-11 | -13.00 |
| 2024-07-08 | -13.89 |
| 2024-07-05 | -14.19 |
| 2024-07-04 | -14.19 |
| 2024-07-02 | -13.89 |
| 2024-06-24 | -13.89 |
| 2024-06-21 | -14.19 |
| 2024-06-20 | -13.89 |
| 2024-06-13 | -14.19 |
| 2024-06-12 | -14.19 |
| 2024-06-10 | -13.89 |
| 2024-06-07 | -13.60 |
| 2024-06-04 | -13.60 |
| 2024-06-03 | -13.00 |
| 2024-05-31 | -13.00 |
| 2024-05-30 | -12.71 |
| 2024-05-29 | -14.19 |
| 2024-05-28 | -13.00 |
| 2024-05-27 | -13.00 |
| 2024-05-24 | -13.30 |
| 2024-05-23 | -13.30 |
| 2024-05-22 | -14.78 |
| 2024-05-21 | -14.19 |
| 2024-05-17 | -14.19 |
| 2024-05-16 | -16.55 |
| 2024-05-15 | -15.96 |
| 2024-05-14 | -16.55 |
| 2024-05-13 | -16.55 |
| 2024-05-10 | -14.48 |
| 2024-05-07 | -16.55 |
| 2024-05-06 | -15.96 |
| 2024-05-03 | -16.55 |
| 2024-05-02 | -16.55 |
| 2024-05-01 | -16.55 |
| 2024-04-30 | -16.85 |
| 2024-04-29 | -17.14 |